Development of classification and response criteria for rheumatic diseases

Singh, Jasvinder A.; Solomon, Daniel H.; Dougados, Maxime; Felson, David T.; Hawker, Gillian; Katz, Patricia; Paulus, H. E.; Wallace, Carol A.

doi:10.1002/art.22003

Cited by 165 publications

(47 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We derived the gout activity score following a data‐driven methodology consistent with that used for other composite measures in rheumatic diseases and in accordance with relevant recommendations 18, 19, 20, 21.…”

Section: Discussionmentioning

confidence: 99%

“…For the purpose of these analyses, the included sample size of >200 subjects is appropriate to develop response criteria according to the recommendations of the ACR Subcommittee on Classification and Response Criteria of the ACR Committee on Quality Measures 18. Therefore, a subsample of 214 patients from the study sample was drawn for the development of the scores.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Development and First Validation of a Disease Activity Score for Gout

Scirè

Carrara

Viroli

et al. 2016

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveTo develop a new composite disease activity score for gout and provide its first validation.MethodsDisease activity has been defined as the ongoing presence of urate deposits that lead to acute arthritis and joint damage. Every measure for each Outcome Measures in Rheumatology core domain was considered. A 3‐step approach (factor analysis, linear discriminant analysis, and linear regression) was applied to derive the Gout Activity Score (GAS). Decision to change treatment or 6‐month flare count were used as the surrogate criteria of high disease activity. Baseline and 12‐month followup data of 446 patients included in the Kick‐Off of the Italian Network for Gout cohort were used. Construct‐ and criterion‐related validity were tested. External validation on an independent sample is reported.ResultsFactor analysis identified 5 factors: patient‐reported outcomes, joint examination, flares, tophi, and serum uric acid (sUA). Discriminant function analysis resulted in a correct classification of 79%. Linear regression analysis identified a first candidate GAS including 12‐month flare count, sUA, visual analog scale (VAS) of pain, VAS global activity assessment, swollen and tender joint counts, and a cumulative measure of tophi. Alternative scores were also developed. The developed GAS demonstrated a good correlation with functional disability (criterion validity) and discrimination between patient‐ and physician‐reported measures of active disease (construct validity). The results were reproduced in the external sample.ConclusionThis study developed and validated a composite measure of disease activity in gout. Further testing is required to confirm its generalizability, responsiveness, and usefulness in assisting with clinical decisions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Development and First Validation of a Disease Activity Score for Gout

Scirè

Carrara

Viroli

et al. 2016

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…We therefore recognize that there is scope for a new skin tool for juvenile DM that takes into account the strengths of the 3 existing tools, to be devised, tested, and validated in large cohorts using robust and internationally agreed standards 22. Until that time we propose the use of a skin VAS and one of these tools in routine practice could improve recognition and prompt treatment of ongoing skin disease in juvenile DM.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis

Campanilho-Marques

Almeida

Deakin

et al. 2016

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveTo compare the abbreviated Cutaneous Assessment Tool (CAT), Disease Activity Score (DAS), and Myositis Intention to Treat Activity Index (MITAX) and correlate them with the physician's 10‐cm skin visual analog scale (VAS) in order to define which tool best assesses skin disease in patients with juvenile dermatomyositis.MethodsA total of 71 patients recruited to the UK Juvenile Dermatomyositis Cohort and Biomarker Study were included and assessed for skin disease using the CAT, DAS, MITAX, and skin VAS. The Childhood Myositis Assessment Scale (CMAS), manual muscle testing of 8 groups (MMT8), muscle enzymes, inflammatory markers, and physician's global VAS were recorded. Relationships were evaluated using Spearman's correlations and predictors with linear regression. Interrater reliability was assessed using intraclass correlation coefficients.ResultsAll 3 tools showed correlation with the physician's global VAS and skin VAS, with DAS skin showing the strongest correlation with skin VAS. DAS skin and CAT activity were inversely correlated with CMAS and MMT8, but these correlations were moderate. No correlations were found between the skin tools and inflammatory markers or muscle enzymes. DAS skin and CAT were the quickest to complete (mean ± SD 0.68 ± 0.1 minutes and 0.63 ± 0.1 minutes, respectively).ConclusionThe 3 skin tools were quick and easy to use. The DAS skin correlated best with the skin VAS. The addition of CAT in a bivariate model containing the physician's global VAS was a statistically significant estimator of skin VAS score. We propose that there is scope for a new skin tool to be devised and tested, which takes into account the strengths of the 3 existing tools.

show abstract

“…The DAS44 was measured according to ACR guidelines by evaluating Ritchie's index, the number of swollen and tender joints, the ESR, and the general health condition. Active disease was considered if DAS44 >3.7, an adequate clinical response was indicated by DAS44-ESR ≤2.4, and remission was considered if DAS44 <1.6 [18]. Response to treatment was assessed at T0, T12, and T24 using the DAS44-ESR improvement criteria, according to which patients who did not achieve at least an adequate clinical response (DAS44-ESR <2.4) or complete remission (DAS44-ESR <1.6) at each visit were considered nonresponders.…”

Section: Methodsmentioning

confidence: 99%

Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics

Chimenti

Teoli²,

Saraceno³

et al. 2013

Dermatology

View full text Add to dashboard Cite

Background: Clinical trials have demonstrated the efficacy of golimumab (GLB) in improving the signs and symptoms of psoriatic arthritis (PsA). Objective: The aim of this study was to evaluate the efficacy of GLB in monotherapy in patients affected by PsA with cutaneous involvement unresponsive to other anti-tumor necrosis factor-α (TNF-α) agents. Methods: This study included 32 patients treated with GLB as monotherapy, at a dosage of 50 mg, subcutaneously, every 4 weeks. Patients were divided into 3 groups (A, B, and C) according to their number of previous anti-TNF-α treatments (1, 2, or 3). Clinical and laboratory evaluations were performed at weeks 0, 12, and 24. Results: All patients showed significant improvement of their clinical, inflammatory, and quality of life indexes. Conclusion: Data suggest that GLB can be successful and safe in patients affected by PsA with skin involvement previously treated with other anti-TNF-α agents.

show abstract

Development of classification and response criteria for rheumatic diseases

Cited by 165 publications

References 12 publications

Development and First Validation of a Disease Activity Score for Gout

Development and First Validation of a Disease Activity Score for Gout

Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis

Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics

Contact Info

Product

Resources

About